Already a member?
Login
Become a member
Register
Menu
Home
About Us
About CGRP Forum
Editorial Board
About CGRP
About CGRP
CGRP and migraine
Unmet needs in migraine prevention
What is the role of CGRP in migraine?
Why is CGRP an important therapeutic target?
Migraine is a complex neurovascular condition
News
News
Meeting Reports
Real World Experience
Hot Topics
Videos
Meet the Expert: Issues and Answers
Trials
Atogepant (AGN-241689)
Erenumab (AMG 334)
Eptinezumab (ALD403)
Galcanezumab (LY2951742)
Fremanezumab (TEV-48125)
Rimegepant (BHV-3000)
Ubrogepant (MK-1602)
Zavegepant (BHV-3500)
Resources
CGRP in the Journals
Meetings
Backgrounders
Slides
Links
Videos
Contact US
Hot off the press: New Forum launches
Latest:
Anti-CGRP therapy mechanisms: Peripheral or central?
The premonitory phase and its treatment – what have we learned?
Top-line SPACE data support fremanezumab efficacy in children
CGRP research points to lymphatic involvement in migraine
CGRP inhibition linked to reduced acne and rosacea
Atogepant effective in medication overuse
Stopping and starting CGRP mAbs can jeopardise response
CGRP mAbs induce connectivity changes in migraine brain
Lars Edvinsson, Rigshospitalet.04/02-2016
Lars Edvinsson, Rigshospitalet.
04/02-2016
Post navigation
Published in
Lars Edvinsson
Trials
Atogepant (AGN-241689)
Erenumab (AMG 334)
Galcanezumab (LY2951742)
Fremanezumab (TEV-48125)
Eptinezumab (ALD403)
Rimegepant (BHV-3000)
Ubrogepant (MK-1602)
Zavegepant (BHV-3500)
Meeting Reports
10th European Academy of Neurology Congress 2024
66th Annual Scientific Meeting of the American Headache Society 2024
76th American Academy of Neurology Annual Meeting 2024
17th European Headache Congress 2023
XXVI World Congress of Neurology 2023
International Headache Congress 2023
9th EAN Congress 2023
65th Annual Scientific Meeting of the American Headache Society 2023
75th American Academy of Neurology Annual Meeting 2023
16th European Headache Congress 2022
Migraine Trust International Symposium 2022
8th Congress of the European Academy of Neurology 2022
64th Annual Meeting of the American Headache Society 2022
American Academy of Neurology 2022
XXV World Congress of Neurology 2021
International Headache Congress 2021
7th Congress of the European Academy of Neurology 2021
63rd Annual Meeting of the American Headache Society 2021
American Academy of Neurology 2021 Virtual Annual Meeting
Migraine Trust International Symposium 2020
14th European Headache Federation Congress 2020
62nd Annual Meeting of the American Headache Society 2020
6th Congress of the European Academy of Neurology 2020
American Academy of Neurology 2020
World Congress of Neurology 2019
IHC 2019
American Headache Society (AHS) 61st Annual Scientific Meeting 2019
5th Congress of the European Academy of Neurology 2019
13th European Headache Federation Congress 2019
American Academy of Neurology Annual Meeting 2019
12th European Headache Federation Congress 2018
17th Biennial Migraine Trust International Symposium 2018
American Headache Society (AHS) 60th Annual Scientific Meeting 2018
4th Congress of the European Academy of Neurology 2018
American Academy of Neurology (AAN) Congress 2018
11th European Headache Federation Congress 2017
18th Congress of the International Headache Society 2017
American Headache Society Annual Scientific Meeting 2017
3rd Congress of the European Academy of Neurology 2017
American Academy of Neurology Annual Meeting 2017
Scottsdale Headache Symposium 2016
The European Headache and Migraine Trust International Congress (EHMTIC) 2016
Resources
Slides
Migraine care in the Middle East: the role of anti-CGRP therapies
Migraine care in Brazil: the role of anti-CGRP therapies
Atogepant
Erenumab
Meetings
Links
Invite a colleague »
MENU
Home
About Us
About CGRP Forum
Editorial Board
About CGRP
About CGRP
CGRP and migraine
Unmet needs in migraine prevention
What is the role of CGRP in migraine?
Why is CGRP an important therapeutic target?
Migraine is a complex neurovascular condition
News
News
Meeting Reports
Real World Experience
Hot Topics
Videos
Meet the Expert: Issues and Answers
Trials
Atogepant (AGN-241689)
Erenumab (AMG 334)
Eptinezumab (ALD403)
Galcanezumab (LY2951742)
Fremanezumab (TEV-48125)
Rimegepant (BHV-3000)
Ubrogepant (MK-1602)
Zavegepant (BHV-3500)
Resources
CGRP in the Journals
Meetings
Backgrounders
Slides
Links
Videos
Contact US